• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Nature reviews. Endocrinology >Technology in the management of type 1 diabetes mellitus - current status and future prospects
【24h】

Technology in the management of type 1 diabetes mellitus - current status and future prospects

机译：1型糖尿病管理中的技术 - 现状和未来前景

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Type 1 diabetes mellitus (T1DM) represents 5-10% of diabetes cases worldwide. The incidence of T1DM is increasing, and there is no immediate prospect of a cure. As such, lifelong management is required, the burden of which is being eased by novel treatment modalities, particularly from the field of diabetes technologies. Continuous glucose monitoring has become the standard of care and includes factory-calibrated subcutaneous glucose monitoring and long-term implantable glucose sensing. In addition, considerable progress has been made in technology-enabled glucose-responsive insulin delivery. The first hybrid insulin-only closed-loop system has been commercialized, and other closed-loop systems are under development, including dual-hormone glucose control systems. This Review focuses on well-established diabetes technologies, including glucose sensing, pen-based insulin delivery, data management and data analytics. We also cover insulin pump therapy, threshold-based suspend, predictive low-glucose suspend and single-hormone and dual-hormone closed-loop systems. Clinical practice recommendations for insulin pump therapy and continuous glucose monitoring are presented, and ongoing research and future prospects are highlighted. We conclude that the management of T1DM is improved by diabetes technology for the benefit of the majority of people with T1DM, their caregivers and guardians and health-care professionals treating patients with T1DM.
机译：1型糖尿病（T1DM）代表全球5-10％的糖尿病病例。 T1DM的发病率越来越大，并且没有立即治愈的前景。因此，需要终身管理，这是新颖的治疗方式所能缓解的，特别是来自糖尿病技术领域。连续葡萄糖监测已成为护理标准，包括工厂校准的皮下葡萄糖监测和长期可植入葡萄糖感应。此外，在能够的技术的葡萄糖响应性胰岛素递送方面取得了相当大的进展。第一杂交胰岛素的闭环系统已被商业化，并且其他闭环系统正在开发中，包括双激素葡萄糖控制系统。本综述重点介绍良好的糖尿病技术，包括葡萄糖传感，基于笔的胰岛素交付，数据管理和数据分析。我们还包括胰岛素泵治疗，基于阈值的悬浮，预测低葡萄糖悬挂和单激素和双激素闭环系统。介绍了胰岛素泵治疗和连续葡萄糖监测的临床实践建议，突出了持续的研究和未来的前景。我们得出结论，糖尿病技术对T1DM的管理得到了改善，因为糖尿病技术为大多数人，他们的照顾者和监护人和医疗保健专业人员治疗T1DM患者的利益。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号